Sveinbjornsdottir S. The clinical symptoms of Parkinson’s disease. J Neurochem. 2016;139:318–24. https://doi.org/10.1111/jnc.13691

Article  CAS  Google Scholar 

Cacabelos R. Parkinson’s disease: from pathogenesis to pharmacogenomics. Int J Mol Sci. 2017;18:551. https://doi.org/10.3390/ijms18030551

Article  CAS  Google Scholar 

Koszła O, Stępnicki P, Zięba A, Grudzińska A, Matosiuk D, Kaczor AA. Current approaches and tools used in drug development against parkinson’s disease. Biomolecules. 2021;11:1–16. https://doi.org/10.3390/biom11060897

Article  CAS  Google Scholar 

Terashi H, Endo K, Kato H, Ido N, Aizawa H. Characteristics of sagittal spinopelvic alignment in patients with Parkinson’s disease. Acta Neurol Scand. 2022;145:53–62. https://doi.org/10.1111/ane.13521

Article  Google Scholar 

Kimber TE. Approach to the patient with early Parkinson disease: diagnosis and management. Intern Med J. 2021;51:20–6. https://doi.org/10.1111/imj.15148

Article  Google Scholar 

Sivanandy P, Leey TC, Xiang TC, Ling TC, Wey Han SA, Semilan SLA, et al. Systemic review on parkinson’s disease medications, emphasizing on three recently approved drugs to control parkinson’s symptoms. Int J Environ Res Public Health. 2022;19. https://doi.org/10.3390/ijerph19010364

Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323:548–60. https://doi.org/10.1001/jama.2019.22360

Article  Google Scholar 

Tian Y, Chen R, Su Z. HMGB1 is a potential and challenging therapeutic target for Parkinson’s disease. Cell Mol Neurobiol. 2021;1:0123456789–58. https://doi.org/10.1007/s10571-021-01170-8

Article  CAS  Google Scholar 

Rozpędek-Kamińska W, Siwecka N, Wawrzynkiewicz A, Wojtczak R, Pytel D, Diehl JA, et al. The PERK-dependent molecular mechanisms as a novel therapeutic target for neurodegenerative diseases. Int J Mol Sci. 2020;21:1–40. https://doi.org/10.3390/ijms21062108

Article  CAS  Google Scholar 

Xu X, He X, Zhang Z, Chen Y, Li J, Ma S, et al. CREB inactivation by HDAC1/PP1c contributes to dopaminergic neurodegeneration in Parkinson’s disease. J Neurosci. 2022;42:4594–604. https://doi.org/10.1523/JNEUROSCI.1419-21.2022

Article  CAS  Google Scholar 

Wittung-stafshede P. Gut power: modulation of human amyloid formation by amyloidogenic proteins in the gastrointestinal tract. Curr Opin Struct Biol. 2022;72:33–38. https://doi.org/10.1016/j.sbi.2021.07.009

Article  CAS  Google Scholar 

Hansen CA, Miller DR, Annarumma S, Rusch CT, Ramirez-Zamora A, Khoshbouei H. Levodopa-induced dyskinesia: a historical review of Parkinson’s disease, dopamine, and modern advancements in research and treatment. J Neurol. 2022;269:2892–909. https://doi.org/10.1007/s00415-022-10963-w

Article  CAS  Google Scholar 

Group PS. A controlled trial of rasagiline in early Parkinson disease. Arch Neurol. 2012;59:1937–43

Google Scholar 

Gallazzi M, Mauri M, Bianchi ML, Riboldazzi G, Princiotta Cariddi L, Carimati F, et al. Selegiline reduces daytime sleepiness in patients with Parkinson’s disease. Brain Behav. 2021;11:1–5. https://doi.org/10.1002/brb3.1880

Article  CAS  Google Scholar 

Meira B, Degos B, Corsetti E, Doulazmi M, Berthelot E, Virbel-Fleischman C, et al. Long-term effect of apomorphine infusion in advanced Parkinson’s disease: a real-life study. npj Parkinson’s Dis. 2021;7:50–61. https://doi.org/10.1038/s41531-021-00194-7

Article  CAS  Google Scholar 

Cennamo M, Dragotto F, Favuzza E, Morelli A, Mencucci R. Amantadine therapy for Parkinson’s Disease: In Vivo Confocal Microscopy corneal findings, case report and revision of literature. BMC Ophthalmol. 2022;22:1–5. https://doi.org/10.1186/s12886-022-02410-1

Article  Google Scholar 

Li B, Yang Y, Wang Y, Zhang J, Ding J, Liu X, et al. Acetylation of NDUFV1 induced by a newly synthesized HDAC6 inhibitor HGC rescues dopaminergic neuron loss in Parkinson models. Science. 2021;24:102302 https://doi.org/10.1016/j.isci.2021.102302

Article  CAS  Google Scholar 

Layton JB, Forns J, Turner ME, Dempsey C, Bartsch JL, Anthony MS, et al. Falls and fractures in patients with Parkinson’s disease-related psychosis treated with Pimavanserin vs atypical antipsychotics: a cohort study. Drugs – Real World Outcomes. 2022;9:9–22. https://doi.org/10.1007/s40801-021-00284-1

Article  Google Scholar 

Zhang X, Che C. Drug repurposing for Parkinson’s disease by integrating knowledge graph completion model and knowledge fusion of medical literature. Future Internet. 2021;13:1–13. https://doi.org/10.3390/fi13010014

Article  Google Scholar 

Reddy DH, Misra S, Medhi B. Advances in drug development for Parkinson’s disease: present status. Pharmacology. 2014;93:260–71. https://doi.org/10.1159/000362419

Article  CAS  Google Scholar 

James JH, Beck C. The silver book: Parkinson’s disease. Chronic disease and medical innovation in an aging nation. Alliance for Aging Research; 2019

Ray Dorsey E, Elbaz A, Nichols E, Abd-Allah F, Abdelalim A, Adsuar JC, et al. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:939–53. https://doi.org/10.1016/S1474-4422(18)30295-3

Article  Google Scholar 

Soto-Lara M, Silva-Loredo M, Monroy-Córdoba JR, Flores-Ordoñez P, Cervera-Delgadillo NG, Carrillo-Mora P. Alternative medicine therapies in neurological disorders: prevalence, reasons and associated factors. A systematic review. Complement Ther Med. 2023;73:0–2. https://doi.org/10.1016/j.ctim.2023.102932

Article  Google Scholar 

Carter AM, Dioso ER, Romero B, Clinker CE, Lucke-Wold B. Complementary medicine and expressive arts therapy: adjuvant for recovery following neurosurgical procedures. OBM Integr Complement Med. 2023;08:1–14. https://doi.org/10.21926/obm.icm.2301007

Article  CAS  Google Scholar 

Jang JH, Kim J, Kwon O, Jung SY, Lee HJ, Cho SY, et al. Effectiveness and therapeutic mechanism of pharmacopuncture for pain in Parkinson’s disease: a study protocol for a pilot pragmatic randomized, assessor-blinded, usual care-controlled, three-arm parallel trial. Int J Environ Res Public Health. 2023;20. https://doi.org/10.3390/ijerph20031776

Calderone A, Formenti M, Aprea F, Papa M, Alberghina L, Colangelo AM, et al. Comparing Alzheimer’s and Parkinson’s diseases networks using graph communities structure. BMC Syst Biol. 2016;10:1–10. https://doi.org/10.1186/s12918-016-0270-7

Article  Google Scholar 

Eliewi AG, Al-Garawi ZS, Al-Kazzaz FF, Atia AJK. Multi target-directed imidazole derivatives for neurodegenerative diseases. J Phys Conf Ser. 2021;1853:0–17. https://doi.org/10.1088/1742-6596/1853/1/012066

Article  CAS  Google Scholar 

Düzel E, Costagli M, Donatelli G, Speck O, Cosottini M. Studying Alzheimer disease, Parkinson disease, and amyotrophic lateral sclerosis with 7-T magnetic resonance. Eur Radiol Exp. 2021;5:36 https://doi.org/10.1186/s41747-021-00221-5

Article  Google Scholar 

Mcgirr S, Venegas C, Swaminathan A. Alzheimer’s disease: a brief review. J Exp Neurol. 2020;1:89–98. https://doi.org/10.33696/Neurol.1.015

Article  Google Scholar 

Marie L. Parkinson’s dementia. The complete guide for people with Parkinson’s disease and their loved ones. 2020. 175–6. https://doi.org/10.2307/j.ctv15wxntx.61

Biswas AK, Das S. Alzheimer and Parkinson’s disease—two faces of the same disease? J Alzheimer’s Dis Parkinson. 2016. 06. https://doi.org/10.4172/2161-0460.1000222

Tamara P, Day GS, Smith DB, Rae-Grant A, Licking N, Armstrong MJ, et al. Dopaminergic therapy for motor symptoms in early Parkinson disease practice Guideline summary. Neurology. 2021;97:942–57. https://doi.org/10.1212/wnl.0000000000012868

Article  Google Scholar 

Kouli A, Torsney KM, Kuan W-L. Parkinson’s disease: etiology, neuropathology, and pathogenesis. Codon Publications. 2018:3–26. https://doi.org/10.15586/codonpublications.parkinsonsdisease.2018

Xia R, Mao ZH. Progression of motor symptoms in Parkinson’s disease. Neurosci Bull. 2012;28:39–48. https://doi.org/10.1007/s12264-012-1050-z

Article  Google Scholar 

Höglund A, Hagell P, Broman JE, Pålhagen S, Sorjonen K, Fredrikson S, et al. Associations between fluctuations in daytime sleepiness and motor and non-motor symptoms in Parkinson’s disease. Mov Disord Clin Pract. 2021;8:44–50. https://doi.org/10.1002/mdc3.13102

Article  Google Scholar 

Dong J, Cui Y, Li S, Le W. Current pharmaceutical treatments and alternative therapies of Parkinson’s disease. Curr Neuropharmacol. 2016;14:339–55. https://doi.org/10.2174/1570159x14666151120123025

Article  CAS  Google Scholar 

Review N, Start WTO, Treatment S, Schapira AHV. Treatment options in the modern management of Parkinson disease. Arch Neurol. 2007;64:1083–8. https://doi.org/10.1001/archneur.64.8.1083

Article  Google Scholar 

Kumaresan M, Khan S. Spectrum of non-motor symptoms in Parkinson’s disease. Cureus. 2021;13. https://doi.org/10.7759/cureus.13275

Sang Q, Liu X, Wang L, Qi L, Sun W, Wang W, et al. CircSNCA downregulation by pramipexole treatment mediates cell apoptosis and autophagy in Parkinson’s disease by targeting miR-7. Aging. 2018;10:1281–93. https://doi.org/10.18632/aging.101466

Article  CAS  Google Scholar 

AlDakheel A, Kalia LV, Lang AE. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics. 2014;11:6–23. https://doi.org/10.1007/s13311-013-0218-1

Article  CAS  Google Scholar 

Cuervo AM, Stafanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant α-synuclein by chaperone-mediated autophagy. Science. 2004;305:1292–5. https://doi.org/10.1126/science.1101738

Article  CAS  Google Scholar 

Paillusson S, Gomez-Suaga P, Stoica R, Little D, Gissen P, Devine MJ, et al. α-Synuclein binds to the ER–mitochondria tethering protein VAPB to disrupt Ca2+ homeostasis and mitochondrial ATP production. Acta Neuropathol. 2017;134:129–49. https://doi.org/10.1007/s00401-017-1704-z

Article  CAS  Google Scholar 

Elkouzi A, Vedam-Mai V, Eisinger RS, Okun MS. Emerging therapies in Parkinson disease—repurposed drugs and new approaches. Nat Rev Neurol. 2019;15:204–23. https://doi.org/10.1038/s41582-019-0155-7

Article  Google Scholar 

Ovallath S, Sulthana B. Levodopa: history and therapeutic applications. Ann Indian Acad Neurol. 2017;20:185–9. https://doi.org/10.4103/aian.AIAN_241_17

Article  Google Scholar 

Goldenberg MM. Medical management of Parkinson’s disease. Pharm Ther. 2008;33:590–6

Google Scholar 

Rao SK, Vakil SD, Calne DB, Hilson A, Rao SK, Lond D, et al. Augmenting the action of levodopa. Postgrad Med J. 1972;48:653–6. https://doi.org/10.1136/pgmj.48.565.653

Article  CAS  Google Scholar 

Ansari AJ, Khushtar M, Fatima N, Monawwar MT, A